Chandraker, A. K., Singh, M., Regmi, A., Ansari, M. J., Lonze, B., Nair, V. V., … Wojciechowski, D. (2022). 310.3: Posoleucel as Preemptive Therapy for BKV Infection in Kidney Transplant Recipients: Safety, Tolerability and Efficacy in a Phase 2 Trial. In Transplantation (Vol. 106, pp. S192–S192). Ovid Technologies (Wolters Kluwer Health). https://doi.org/10.1097/01.tp.0000886340.34492.e9

Chandraker, Anil K., Manpreet Singh, Anil Regmi, M Javeed Ansari, Bonnie Lonze, Vinay V. Nair, Akhil Sharma, et al. “310.3: Posoleucel as Preemptive Therapy for BKV Infection in Kidney Transplant Recipients: Safety, Tolerability and Efficacy in a Phase 2 Trial.” In Transplantation, 106:S192–S192. Ovid Technologies (Wolters Kluwer Health), 2022. https://doi.org/10.1097/01.tp.0000886340.34492.e9.

Chandraker AK, Singh M, Regmi A, Ansari MJ, Lonze B, Nair VV, et al. 310.3: Posoleucel as Preemptive Therapy for BKV Infection in Kidney Transplant Recipients: Safety, Tolerability and Efficacy in a Phase 2 Trial. In: Transplantation. Ovid Technologies (Wolters Kluwer Health); 2022. p. S192–S192.

Chandraker, Anil K., et al. “310.3: Posoleucel as Preemptive Therapy for BKV Infection in Kidney Transplant Recipients: Safety, Tolerability and Efficacy in a Phase 2 Trial.” Transplantation, vol. 106, no. 9S, Ovid Technologies (Wolters Kluwer Health), 2022, pp. S192–S192. Crossref, doi:10.1097/01.tp.0000886340.34492.e9.

Chandraker AK, Singh M, Regmi A, Ansari MJ, Lonze B, Nair VV, Sharma A, Knechtle SJ, Cardarelli F, Marshall W, Wojciechowski D. 310.3: Posoleucel as Preemptive Therapy for BKV Infection in Kidney Transplant Recipients: Safety, Tolerability and Efficacy in a Phase 2 Trial. Transplantation. Ovid Technologies (Wolters Kluwer Health); 2022. p. S192–S192.